Breast Biopsy Devices Market: How the Business Will Grow in 2023?

The various factor positively impacting the market are surging incidence of breast cancer, technological advancements in breast imaging equipment, aging women population, growing number of breast screening programs, and rising demand for minimally invasive surgeries. Breast biopsy devices remove tissue or sometimes fluid from the suspicious area, which is then examined under a microscope and tested further to check for the presence of breast cancer.

Receive a Free Sample Copy of this Report:https://www.psmarketresearch.com/market-analysis/breast-biopsy-devices-market/report-sample

In terms of imaging modality, the breast biopsy devices market is divided into ultrasound guided biopsy, computed tomography (CT) guided biopsy, mammography guided stereotactic biopsy, magnetic resonance imaging (MRI) guided biopsy, and others (which include breast thermography, positron emission tomography guided, and percutaneous image-guided core breast biopsy). Out of these, the mammography guided stereotactic division held the largest share of the market during the historical period and is projected to retain its position during the forecast period. The fastest growth is projected to be witnessed by the ultrasound guided biopsy during the forecast period.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=breast-biopsy-devices-market

A major factor driving the growth of the breast biopsy devices market is the rising incidence of breast cancer. Breast cancer is the abnormal or uncontrolled growth of cells, which results in the formation of a tumor. It is one of the most common cancer in women across the world. As per the National Cancer Institute, approximately 3,327,552 women were living with breast cancer in the U.S. in 2017. In addition to this, death rates because of breast cancer among the women in the U.S. are higher than any other cancer, besides lung cancer.

A key trend in the breast biopsy devices market is the emergence of liquid biopsy, which is a non-invasive and low-risk procedure. It is utilized for detecting cancer-related genetic profile and routine monitoring of therapeutic responses over time. As the cancer cells die and proliferate, DNA is released, some of which makes its way to the circulatory systems, thereby making it available for detection. Since this method can detect the presence of cancer at an early stage, several companies are adopting this technology for the detection of breast cancer.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.